TD Cowen Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $18.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective lowered by TD Cowen from $49.00 to $18.00 in a report released on Thursday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald dropped their price objective on shares of Ultragenyx Pharmaceutical from $103.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday. Evercore lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price for the company. in a report on Thursday. JPMorgan Chase & Co. cut Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $80.00 to $36.00 in a research report on Thursday. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada raised their price objective on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $36.63.

Ultragenyx Pharmaceutical Trading Up 3.0%

Shares of RARE stock opened at $15.30 on Thursday. Ultragenyx Pharmaceutical has a 12 month low of $13.81 and a 12 month high of $39.89. The stock has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31. The company’s fifty day moving average price is $27.76 and its 200-day moving average price is $24.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s revenue was up 28.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.17) EPS. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Parschauer sold 1,899 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at approximately $528,429.75. The trade was a 8.66% decrease in their position. The SEC filing for this sale provides additional information. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares during the last quarter. Creative Planning purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $454,000. American Century Companies Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth $366,000. M&T Bank Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 19.7% during the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock valued at $263,000 after purchasing an additional 1,192 shares in the last quarter. Finally, Amundi lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,560.4% during the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after purchasing an additional 93,189 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.